PMID- 12105115
OWN - NLM
STAT- MEDLINE
DCOM- 20020802
LR  - 20220410
IS  - 0077-8923 (Print)
IS  - 0077-8923 (Linking)
VI  - 965
DP  - 2002 Jun
TI  - Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release.
PG  - 399-409
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) has been reported to cause 
      hyponatraemia, which appears to result from inappropriate secretion of the 
      antidiuretic hormone arginine vasopressin (AVP). After administration of a low 
      dose of (R,S)-MDMA (40 mg) to eight healthy drug-free male volunteers, 
      concentrations of AVP in plasma increased significantly at 1, 2, and 4 hours. 
      Although no relation between plasma MDMA and AVP was found on an examination of 
      the entire data set over the 24-hour study period, a statistically significant 
      negative correlation was observed at 1 hour. As this occurred at a time when both 
      AVP and MDMA concentrations were rising, it was postulated that a metabolite, or 
      metabolites, could primarily be responsible for the increase in AVP. To test this 
      hypothesis we examined the effect of MDMA and five of its metabolites, in the 
      dose range 0.1-1,000 nM, on AVP release from the isolated rat hypothalamus. All 
      compounds tested were found to increase AVP release (using 10 nM and 1,000 nM 
      concentrations), with 4-hydroxy-3-methoxymethamphetamine (HMMA), the major 
      metabolite of MDMA, being the most potent, and 3,4-dihydroxymethamphetamine 
      (DHMA) the least potent. Each compound (1,000 nM), with the exception of DHMA, 
      also enhanced the response to 40-mM potassium stimulation. Our findings confirm 
      that metabolites of MDMA, in addition to the parent drug, contribute to AVP 
      secretion in vitro. Further work will demonstrate whether this is also true in 
      vivo.
FAU - Fallon, J K
AU  - Fallon JK
AD  - Drug Control Centre and Department of Pharmacy, King's College London, 
      Franklin-Wilkins Building, London SE1 9NN, UK.
FAU - Shah, D
AU  - Shah D
FAU - Kicman, A T
AU  - Kicman AT
FAU - Hutt, A J
AU  - Hutt AJ
FAU - Henry, J A
AU  - Henry JA
FAU - Cowan, D A
AU  - Cowan DA
FAU - Forsling, M
AU  - Forsling M
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Ann N Y Acad Sci
JT  - Annals of the New York Academy of Sciences
JID - 7506858
RN  - 113-79-1 (Arginine Vasopressin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Arginine Vasopressin/blood/*metabolism
MH  - Dose-Response Relationship, Drug
MH  - Hypothalamus/drug effects/*physiology
MH  - In Vitro Techniques
MH  - Kinetics
MH  - Male
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*analogs & derivatives/blood/*pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Stereoisomerism
EDAT- 2002/07/10 10:00
MHDA- 2002/08/03 10:01
CRDT- 2002/07/10 10:00
PHST- 2002/07/10 10:00 [pubmed]
PHST- 2002/08/03 10:01 [medline]
PHST- 2002/07/10 10:00 [entrez]
AID - 10.1111/j.1749-6632.2002.tb04181.x [doi]
PST - ppublish
SO  - Ann N Y Acad Sci. 2002 Jun;965:399-409. doi: 10.1111/j.1749-6632.2002.tb04181.x.